Thirty eight patients with known or suspected phaeochromocytoma were studied by radioisotope imaging after intravenous administration of iodine-131-meta-iodobenzylguanidine (1311-mIBG), a radiopharmaceutical which has affinity for chromaffin tumours. Seventeen positive results (including one false positive) and 21 negative results(including two false negatives) were obtained. Clinical accuracy was 92%. Urinary noradrenaline concentrations were raised in all patients with confirmed phaeochromocytoma.
Introduction
Iodine-131-meta-iodobenzylguanidine (13"I-mIBG) has been shown to be concentrated in chromaffin tissue, and imaging with a gammacamera can localise phaeochromocytoma in man. -4 This non-invasive investigation is a promising addition to the management of this potentially lethal condition. We present the results of 13II-mIBG imaging and measurement of urinary catecholamine concentrations in 38 patients.
Meta-iodobenzylguanidine sulphate was prepared from metaiodobenzylamine and cyanamide5 and purified by recrystallisation. Administration to Sprague-Dawley rats of 1200 times the equivalent dose in man gave no evidence of sublethal toxicity or mortality. Labelling with 131I was carried out by a modified solid phase method.6 Patients were investigated either in hospital or as outpatients over four or five days. Labelled mIBG was administered on day 1 by slow intravenous injection over several minutes, with patient monitoring. On days 2, 3, and 4 images were obtained of the head and neck, thorax, abdomen, and pelvis in the anterior and posterior positions using a wide field of view gammacamera with data acquisition. Carefully positioned marker sources permitted precise orientation of each of the eight views from one day to the next.
Most patients received 20 MBq (0-5 mCi) 131I-mIBG for imaging. Higher activities were administered to patients with known malignant phaeochromocytoma and to some with extra-adrenal tumours. One was studied with 123I-mIBG. Two patients were subjected to repeat imaging, and two with malignancy were treated with high activity 311-mIBG.
Sequential 24 hour urine collections were analysed for urinary free noradrenaline, adrenaline, and dopamine concentrations using high performance liquid chromatography with electrochemical detection. 7 Results Tables I and II give details of a sample of the patients studied.
IMAGING
All patients showed the reported normal tissue distribution of 13I-mIBG in liver, spleen, bladder, salivary glands, and other tissues.8 In none was the normal adrenal medulla perceived. Of the 38 patients, 17 showed evidence of positive 131I-mIBG localisation and 21 showed 
Discussion
Computed tomography is the most accurate imaging technique at present for localising tumours within the adrenal gland.9-'2 It is more sensitive and specific than intravenous urography and less invasive than arteriography. Ultrasound is less accurate at detecting tumours" and may not always show the normal adrenal, particularly the left.1' It is less certain how accurate these techniques are for showing chromaffin tumours sited outside the adrenal gland, or for multifocal or malignant tumours. Our results indicate that "3'I-mIBG has considerable promise for the management of patients with phaeochromocytoma. It is taken up by most phaeochromocytomas regardless of site, and screening with the gammacamera readily localises the tumour.
The mechanism of uptake of mIBG is thought to be similar to that of noradrenaline storage in chromaffin tissue. Studies in animals show that uptake is not influenced by drugs commonly used for treatment but that reserpine"5 and tricyclic antidepressants' have an inhibitory effect. So far there is no known pharmacological or other method for enhancing the uptake or retention of mIBG by chromaffin tumours.
All but one of our patients with malignant phaeochromocytoma had bone metastases, and we find radioisotope skeletal imaging with technetium-99m methylene diphosphonate valuable in establishing a diagnosis of malignancy, particularly as this cannot be done on histological grounds. Much has been written on the relevance of catecholamine excretion patterns in patients with phaeochromocytoma.'6
Raised urinary concentrations of adrenaline usually indicate an intra-adrenal tumour. This was true for four of our patients, though three others had normal values. One possible reason for this impaired conversion of noradrenaline to adrenaline is poor induction of phenylethanolamine-N-methyltransferase by adrenocortical steroids,'7 possibly due to impaired blood flow in the tumour. This study confirms that urinary dopamine concentrations cannot be used to diagnose malignancy.'8 Nevertheless, normal values in three of our patients with known metastases correlated with "benign" progression of the disease. Conversely, patients with "aggressive" malignancy had raised values, one patient excreting normal amounts initially but having a high value shortly before death. This suggests that dopamine excretion might be used as a prognostic sign in the progression of malignant phaeochromocytoma.
We
Labelled mIBG has also been used to treat patients with malignant phaeochromocytoma.20 Two of our patients (cases 1 and 2) received therapeutic doses. The first patient already had advanced malignancy, and administration of mIBG did not alter the progression of this and she died. The second patient showed some symptomatic response but there was no alteration in catecholamine concentrations or tumour bulk. It is too early to anticipate the value of this approach in the treatment of malignant phaeochromocytoma.
Administration of mIBG has two potential hazards. Firstly, it may have a pharmacological effect by displacing catecholamines from tumour tissue. We used 0-2 mg for most imaging studies and up to 6 mg as a therapeutic dose. No adverse effects were observed in any of our patients, and there was no alteration in pulse rate, blood pressure, or temperature after infusion of mIBG. The 
